CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 15:55 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 08:00 ET
|
Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024 08:00 ET
|
Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024 10:00 ET
|
Science 37, Inc.
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
May 02, 2024 08:00 ET
|
Science 37, Inc.
Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial.
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
April 17, 2024 08:00 ET
|
Science 37, Inc.
Science 37's Patient Recruitment Solution provides fully-consented patients to clinical trial sites to supplement enrollment.
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
January 29, 2024 07:30 ET
|
Science 37, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today...
Science 37 Receives Top Honors in Everest PEAK Matrix®
December 12, 2023 08:00 ET
|
Science 37, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a...
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2023 16:59 ET
|
Science 37, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards...
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
December 05, 2023 07:00 ET
|
Science 37, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced...